After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More

StreetInsider2022-03-16

After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Simonnov
2022-03-16
Simonnov
Ic
Looyusooi
2022-03-16
Looyusooi
Ok
Bspn
2022-03-16
Bspn
Ok
Samuel123win
2022-03-16
Samuel123win
V
ccy1122
2022-03-16
ccy1122
[Call] [Call] [Call] [Heart] [Heart] [Heart] [666] [666] [666]
imsomeonelse
2022-03-16
imsomeonelse
Everything's up

Leave a comment

380

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2219372817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-03-16 07:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2219372817","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-16 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19780631><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=19780631","article_id":"2219372817","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2219372817","pubTimestamp":1647386525,"columns":[],"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the ","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SMAR":"Smartsheet","BK4161":"工业机械","BK4022":"陆运","BK4561":"索罗斯持仓","CAL":"Caleres鞋业","BK4528":"SaaS概念","BK4097":"系统软件","BIRD":"Allbirds, Inc.","IOVA":"Iovance Biotherapeutics, Inc.","BRDS":"Bird Global","MKFG":"Markforged Holding Corporation","BK4560":"网络安全概念","S":"SentinelOne, Inc"},"translate_title":"下班后的股票搬运工：哨兵龙、艾尔伯德、催化剂生物科学、Iovance生物疗法等","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRDS":1,"CBIO":1,"IOVA":1,"MKFG":1,"S":1,"SMAR":1,"BIRD":0.9,"CAL":0.9},"content_text":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.Markforged Holding Corporation (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 millionSmartsheet (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.Bird Global (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.SentinelOne, Inc. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.Allbirds, Inc. (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9032569366,"gmtCreate":1647400854398,"gmtModify":1676534225552,"author":{"id":"4097750438225520","authorId":"4097750438225520","name":"Simonnov","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4097750438225520","authorIdStr":"4097750438225520"},"htmlText":"Ic","listText":"Ic","text":"Ic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032569366","repostId":2219372817,"repostType":4,"repost":{"id":"2219372817","kind":"news","pubTimestamp":1647386525,"share":"https://ttm.financial/m/news/2219372817?lang=&edition=fundamental","pubTime":"2022-03-16 07:22","market":"us","language":"en","title":"After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2219372817","media":"StreetInsider","summary":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the ","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p><a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry <a href=\"https://laohu8.com/S/AMD\">AMD</a> (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.</p><p><a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics, Inc.</a> (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.</p><p><a href=\"https://laohu8.com/S/MKFG\">Markforged Holding Corporation</a> (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 million</p><p><a href=\"https://laohu8.com/S/SMAR\">Smartsheet</a> (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.</p><p><a href=\"https://laohu8.com/S/BRDS\">Bird Global</a> (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.</p><p><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a>. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.</p><p>Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.</p><p><a href=\"https://laohu8.com/S/BIRD\">Allbirds, Inc.</a> (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152</p><p>Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-16 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19780631><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAL":"Caleres鞋业","BK4022":"陆运","IOVA":"Iovance Biotherapeutics, Inc.","BK4097":"系统软件","BK4561":"索罗斯持仓","S":"SentinelOne, Inc","BK4139":"生物科技","BK4528":"SaaS概念","BIRD":"Allbirds, Inc.","BRDS":"Bird Global","BK4560":"网络安全概念","SMAR":"Smartsheet","MKFG":"Markforged Holding Corporation","BK4161":"工业机械"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19780631","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2219372817","content_text":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.Markforged Holding Corporation (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 millionSmartsheet (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.Bird Global (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.SentinelOne, Inc. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.Allbirds, Inc. (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032535156,"gmtCreate":1647396434576,"gmtModify":1676534224893,"author":{"id":"4100437715079400","authorId":"4100437715079400","name":"Looyusooi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4100437715079400","authorIdStr":"4100437715079400"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032535156","repostId":2219372817,"repostType":4,"repost":{"id":"2219372817","kind":"news","pubTimestamp":1647386525,"share":"https://ttm.financial/m/news/2219372817?lang=&edition=fundamental","pubTime":"2022-03-16 07:22","market":"us","language":"en","title":"After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2219372817","media":"StreetInsider","summary":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the ","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p><a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry <a href=\"https://laohu8.com/S/AMD\">AMD</a> (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.</p><p><a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics, Inc.</a> (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.</p><p><a href=\"https://laohu8.com/S/MKFG\">Markforged Holding Corporation</a> (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 million</p><p><a href=\"https://laohu8.com/S/SMAR\">Smartsheet</a> (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.</p><p><a href=\"https://laohu8.com/S/BRDS\">Bird Global</a> (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.</p><p><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a>. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.</p><p>Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.</p><p><a href=\"https://laohu8.com/S/BIRD\">Allbirds, Inc.</a> (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152</p><p>Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-16 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19780631><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAL":"Caleres鞋业","BK4022":"陆运","IOVA":"Iovance Biotherapeutics, Inc.","BK4097":"系统软件","BK4561":"索罗斯持仓","S":"SentinelOne, Inc","BK4139":"生物科技","BK4528":"SaaS概念","BIRD":"Allbirds, Inc.","BRDS":"Bird Global","BK4560":"网络安全概念","SMAR":"Smartsheet","MKFG":"Markforged Holding Corporation","BK4161":"工业机械"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19780631","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2219372817","content_text":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.Markforged Holding Corporation (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 millionSmartsheet (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.Bird Global (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.SentinelOne, Inc. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.Allbirds, Inc. (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032597892,"gmtCreate":1647395344775,"gmtModify":1676534224590,"author":{"id":"3582502134655895","authorId":"3582502134655895","name":"Bspn","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582502134655895","authorIdStr":"3582502134655895"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032597892","repostId":2219372817,"repostType":4,"repost":{"id":"2219372817","kind":"news","pubTimestamp":1647386525,"share":"https://ttm.financial/m/news/2219372817?lang=&edition=fundamental","pubTime":"2022-03-16 07:22","market":"us","language":"en","title":"After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2219372817","media":"StreetInsider","summary":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the ","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p><a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry <a href=\"https://laohu8.com/S/AMD\">AMD</a> (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.</p><p><a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics, Inc.</a> (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.</p><p><a href=\"https://laohu8.com/S/MKFG\">Markforged Holding Corporation</a> (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 million</p><p><a href=\"https://laohu8.com/S/SMAR\">Smartsheet</a> (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.</p><p><a href=\"https://laohu8.com/S/BRDS\">Bird Global</a> (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.</p><p><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a>. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.</p><p>Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.</p><p><a href=\"https://laohu8.com/S/BIRD\">Allbirds, Inc.</a> (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152</p><p>Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-16 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19780631><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAL":"Caleres鞋业","BK4022":"陆运","IOVA":"Iovance Biotherapeutics, Inc.","BK4097":"系统软件","BK4561":"索罗斯持仓","S":"SentinelOne, Inc","BK4139":"生物科技","BK4528":"SaaS概念","BIRD":"Allbirds, Inc.","BRDS":"Bird Global","BK4560":"网络安全概念","SMAR":"Smartsheet","MKFG":"Markforged Holding Corporation","BK4161":"工业机械"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19780631","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2219372817","content_text":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.Markforged Holding Corporation (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 millionSmartsheet (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.Bird Global (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.SentinelOne, Inc. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.Allbirds, Inc. (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032506837,"gmtCreate":1647393572287,"gmtModify":1676534224168,"author":{"id":"4092554906611330","authorId":"4092554906611330","name":"Samuel123win","avatar":"https://static.tigerbbs.com/fb615bd9d23d3ee707625d59ccb06f5e","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":1,"crmLevelSwitch":0,"idStr":"4092554906611330","authorIdStr":"4092554906611330"},"htmlText":"V","listText":"V","text":"V","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032506837","repostId":2219372817,"repostType":4,"repost":{"id":"2219372817","kind":"news","pubTimestamp":1647386525,"share":"https://ttm.financial/m/news/2219372817?lang=&edition=fundamental","pubTime":"2022-03-16 07:22","market":"us","language":"en","title":"After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2219372817","media":"StreetInsider","summary":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the ","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p><a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry <a href=\"https://laohu8.com/S/AMD\">AMD</a> (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.</p><p><a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics, Inc.</a> (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.</p><p><a href=\"https://laohu8.com/S/MKFG\">Markforged Holding Corporation</a> (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 million</p><p><a href=\"https://laohu8.com/S/SMAR\">Smartsheet</a> (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.</p><p><a href=\"https://laohu8.com/S/BRDS\">Bird Global</a> (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.</p><p><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a>. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.</p><p>Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.</p><p><a href=\"https://laohu8.com/S/BIRD\">Allbirds, Inc.</a> (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152</p><p>Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-16 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19780631><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAL":"Caleres鞋业","BK4022":"陆运","IOVA":"Iovance Biotherapeutics, Inc.","BK4097":"系统软件","BK4561":"索罗斯持仓","S":"SentinelOne, Inc","BK4139":"生物科技","BK4528":"SaaS概念","BIRD":"Allbirds, Inc.","BRDS":"Bird Global","BK4560":"网络安全概念","SMAR":"Smartsheet","MKFG":"Markforged Holding Corporation","BK4161":"工业机械"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19780631","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2219372817","content_text":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.Markforged Holding Corporation (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 millionSmartsheet (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.Bird Global (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.SentinelOne, Inc. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.Allbirds, Inc. (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032276270,"gmtCreate":1647392481799,"gmtModify":1676534223924,"author":{"id":"4103860021943040","authorId":"4103860021943040","name":"ccy1122","avatar":"https://static.itradeup.com/news/562c0e01bcfc63800f64741051cd9dbe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4103860021943040","authorIdStr":"4103860021943040"},"htmlText":"[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Heart]&nbsp;[Heart]&nbsp;[Heart]&nbsp;[666]&nbsp;[666]&nbsp;[666]&nbsp;","listText":"[Call]&nbsp;[Call]&nbsp;[Call]&nbsp;[Heart]&nbsp;[Heart]&nbsp;[Heart]&nbsp;[666]&nbsp;[666]&nbsp;[666]&nbsp;","text":"[Call] [Call] [Call] [Heart] [Heart] [Heart] [666] [666] [666]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032276270","repostId":2219372817,"repostType":2,"repost":{"id":"2219372817","kind":"news","pubTimestamp":1647386525,"share":"https://ttm.financial/m/news/2219372817?lang=&edition=fundamental","pubTime":"2022-03-16 07:22","market":"us","language":"en","title":"After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2219372817","media":"StreetInsider","summary":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the ","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p><a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry <a href=\"https://laohu8.com/S/AMD\">AMD</a> (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.</p><p><a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics, Inc.</a> (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.</p><p><a href=\"https://laohu8.com/S/MKFG\">Markforged Holding Corporation</a> (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 million</p><p><a href=\"https://laohu8.com/S/SMAR\">Smartsheet</a> (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.</p><p><a href=\"https://laohu8.com/S/BRDS\">Bird Global</a> (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.</p><p><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a>. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.</p><p>Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.</p><p><a href=\"https://laohu8.com/S/BIRD\">Allbirds, Inc.</a> (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152</p><p>Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-16 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19780631><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAL":"Caleres鞋业","BK4022":"陆运","IOVA":"Iovance Biotherapeutics, Inc.","BK4097":"系统软件","BK4561":"索罗斯持仓","S":"SentinelOne, Inc","BK4139":"生物科技","BK4528":"SaaS概念","BIRD":"Allbirds, Inc.","BRDS":"Bird Global","BK4560":"网络安全概念","SMAR":"Smartsheet","MKFG":"Markforged Holding Corporation","BK4161":"工业机械"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19780631","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2219372817","content_text":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.Markforged Holding Corporation (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 millionSmartsheet (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.Bird Global (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.SentinelOne, Inc. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.Allbirds, Inc. (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9032227783,"gmtCreate":1647390033410,"gmtModify":1676534223278,"author":{"id":"3572697049328629","authorId":"3572697049328629","name":"imsomeonelse","avatar":"https://community-static.tradeup.com/news/9294e9e7f11f190688efe808098fa12b","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3572697049328629","authorIdStr":"3572697049328629"},"htmlText":"Everything's up","listText":"Everything's up","text":"Everything's up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032227783","repostId":2219372817,"repostType":4,"repost":{"id":"2219372817","kind":"news","pubTimestamp":1647386525,"share":"https://ttm.financial/m/news/2219372817?lang=&edition=fundamental","pubTime":"2022-03-16 07:22","market":"us","language":"en","title":"After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More","url":"https://stock-news.laohu8.com/highlight/detail?id=2219372817","media":"StreetInsider","summary":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the ","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p><a href=\"https://laohu8.com/S/CBIO\">Catalyst Biosciences</a>, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry <a href=\"https://laohu8.com/S/AMD\">AMD</a> (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.</p><p><a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics, Inc.</a> (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.</p><p><a href=\"https://laohu8.com/S/MKFG\">Markforged Holding Corporation</a> (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 million</p><p><a href=\"https://laohu8.com/S/SMAR\">Smartsheet</a> (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.</p><p><a href=\"https://laohu8.com/S/BRDS\">Bird Global</a> (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.</p><p><a href=\"https://laohu8.com/S/S\">SentinelOne, Inc</a>. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.</p><p>Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.</p><p><a href=\"https://laohu8.com/S/BIRD\">Allbirds, Inc.</a> (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152</p><p>Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: SentinelOne, Allbirds, Catalyst Biosciences, Iovance Biotherapeutics and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-16 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19780631><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19780631\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CAL":"Caleres鞋业","BK4022":"陆运","IOVA":"Iovance Biotherapeutics, Inc.","BK4097":"系统软件","BK4561":"索罗斯持仓","S":"SentinelOne, Inc","BK4139":"生物科技","BK4528":"SaaS概念","BIRD":"Allbirds, Inc.","BRDS":"Bird Global","BK4560":"网络安全概念","SMAR":"Smartsheet","MKFG":"Markforged Holding Corporation","BK4161":"工业机械"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19780631","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2219372817","content_text":"After-Hours Stock Movers:Catalyst Biosciences, Inc. (NASDAQ: CBIO) 14.6% HIGHER; announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments.Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.Markforged Holding Corporation (NYSE: MKFG) 9.4% HIGHER; reported Q4 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.51 million. Markforged Holding Corporation sees FY2022 revenue of $114-123 million, versus the consensus of $120.3 millionSmartsheet (NYSE: SMAR) 6.9% LOWER; reported Q4 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $157.4 million versus the consensus estimate of $151.66 million. Smartsheet sees Q1 2023 EPS of ($0.20)-($0.18), versus the consensus of ($0.11). Smartsheet sees Q1 2023 revenue of $162-163 million, versus the consensus of $159.83 million. Smartsheet sees FY2023 EPS of ($0.70)-($0.62), versus the consensus of ($0.27). Smartsheet sees FY2023 revenue of $750-755 million, versus the consensus of $730.11 million.Bird Global (NYSE: BRDS) 6.3% LOWER; reported Q4 revenue of $54 million versus the consensus estimate of $50.78 million. Bird Global sees Q1 2022 revenue of $34-36 million, versus the consensus of $49 million. Bird Global sees FY2022 revenue of at least $350 million, versus the consensus of $381.7 million.SentinelOne, Inc. (NYSE: S) 4.5% LOWER; reported Q4 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $65.6 million versus the consensus estimate of $60.65 million. SentinelOne, Inc. sees Q1 2023 revenue of $74-75 million, versus the consensus of $68.2 million. SentinelOne, Inc. sees FY2023 revenue of $366-370 million, versus the consensus of $346.2 million.Caleres (NYSE: CAL) 4.4% HIGHER; reported Q4 EPS of $0.91, $0.24 better than the analyst estimate of $0.67. Revenue for the quarter came in at $679.3 million versus the consensus estimate of $677.21 million. Caleres sees FY2022 EPS of $3.75-$4.00, versus the consensus of $4.03.Allbirds, Inc. (NASDAQ: BIRD) 4.2% HIGHER; CFO, Michael Bufano, bought 25,000 shares on 03/14/22 at an average price of $5.1661. The value of the transaction was $129,152Butterfly Network (NYSE: BFLY) 2% HIGHER; Director, Larry Robbins of Glenview Capital, bought 500,000 shares through the hedge fund.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":380,"commentSize":94,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2219372817"}